-7 mol/L胰島素誘導(dǎo)HepG2細(xì)胞,建立IR細(xì)胞模型;MTT法檢測羈糖脂對HepG2細(xì)胞的增殖抑制率;葡萄糖氧化酶-過氧化物酶(GOD-POD)法檢測羈糖脂對HepG2 IR細(xì)胞葡萄糖吸收的影響;Western blotting法檢測胰島素受體底物1磷酸化絲氨酸p-IRS-1(Ser307)、磷酸酰肌醇-3-激酶(PI3K)、葡萄糖轉(zhuǎn)運(yùn)體-4(GLUT-4)的表達(dá)。結(jié)果 HepG2細(xì)胞置于含10-7胰島素培養(yǎng)液孵育24 h,與對照組比較,葡萄糖吸收水平下降,表明建模成功;30~120 μg/mL羈糖脂均能顯著增加IR細(xì)胞葡萄糖吸收率,顯著上調(diào)GLUT-4、PI3K蛋白表達(dá)水平,顯著下調(diào)IRS-1 Ser307磷酸化水平。結(jié)論 羈糖脂能有效增強(qiáng)HepG2 IR細(xì)胞對葡萄糖的消耗能力,推測與上調(diào)GLUT-4、PI3K蛋白表達(dá),抑制IRS-1絲氨酸磷酸化相關(guān)。;Objective To evaluate the effect of Ji Tang Zhi on glucose metabolism in insulin resistance (IR) HepG 2 cell line, and to explore the related mechanism. Methods The HepG2 cells were incubated in culture medium addition of 10-7 mol/L insulin for 24 h to establish the IR cell model. Effect of Ji Tang Zhi on rate of glucose absorption in HepG2 cell was detected by the method of glucose oxidase-peroxidase (GOD-POD). We performed an MTT assay to determine cytotoxicity effects of Ji Tang Zhi on HepG2 cell line. The expression of p-IRS-1 Ser307, PI3K and GLUT-4 were detected by Western blotting. Results Incubated with 10-7 mol/L insulin for 24 h, the insulin resistance cell model had been built. Compared with model group, the rate of glucose absorption of cell treated with JTZ (30 ~120 μg/mL) was significantly improved. According to model cells, the expression of GLUT-4 and PI3K decreased significantly compared to control cells. While the expression of p-IRS-1 Ser 307 was inhibited and GLUT-4 and PI3K expression were increased in IR cells after treated with JTZ (30 ~120 μg/mL). Conclusion JTZ exert beneficial effects on hyperglycosemia in IR cell line possibly through regulating the levels of GLUT-4, p-IRS-1 Ser307 and PI3K in HepG2 cell."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2017年第40卷第6期 >2017,40(6):783-787. DOI:10.7501/j.issn.1674-6376.2017.06.010
上一篇 | 下一篇

羈糖脂對HepG2胰島素抵抗細(xì)胞葡萄糖代謝及相關(guān)蛋白表達(dá)的影響

Effects of Ji Tang Zhi on glucose metabolism and related protein expression in insulin resistance HepG 2 cell line

發(fā)布日期:2017-08-09
您是第位訪問者
藥物評價(jià)研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031